Loading
A phase 1/2 trial of SHR-A2102, Adebrelimab, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT06512051 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 248 participants planned, started 2024-07-30 and due to reach its primary completion in 2026-10. Interventions recorded: SHR-A2102 for Injection, Adebrelimab Injection, Cisplatin injection, Carboplatin injection, Bevacizumab Injection. Conditions listed: Advanced or Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Carboplatin.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Monoclonal antibodies.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Carboplatin, Small-cell lung cancer.